SCHEDULE: CVI Investments, Heights Capital Disclose 9.9% Stake in Citius Pharma

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a combined beneficial ownership of 9.9% in Citius Pharmaceuticals, Inc. common stock.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Citius Pharmaceuticals, Inc.
• The Reporting Persons collectively beneficially own 2,394,725 shares of Citius Pharmaceuticals, Inc. common stock.
• This represents 9.9% of the company's outstanding common stock, based on 22,376,427 shares outstanding as of December 31, 2025.
• The ownership includes 799,934 existing shares and additional shares issuable upon the exercise of warrants.
• Warrant exercisability is limited to prevent beneficial ownership from exceeding 4.99% or 9.99% thresholds, depending on the specific warrants, to comply with Section 13(d) of the Exchange Act.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and holds shared voting and dispositive power over these shares.
• The filing indicates that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a standard disclosure of an institutional investor's passive stake and does not contain new operational or financial information about Citius Pharmaceuticals itself.

Future Outlook

No forward-looking statements or guidance from Citius Pharmaceuticals are provided in this investor filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, indicating a passive investment intent. This filing confirms a significant, but non-controlling, stake by CVI Investments and Heights Capital Management in Citius Pharmaceuticals, a common occurrence for publicly traded companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially signaling investor confidence, though the intent is passive.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive institutional ownership stake and does not contain new material information regarding Citius Pharmaceuticals' operational performance, financial health, or strategic direction. Therefore, it does not warrant a change in investment thesis based on this document alone, suggesting a 'hold' position for existing investors.

Keywords

Citius Pharmaceuticals, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, CTXR, Warrants